Evidence map›Paper›PMID 28681250›Full record

Observational studyRheumatology international2017

Prevalence of comorbidities in Mexican mestizo patients with rheumatoid arthritis.

Dionicio A Galarza-Delgado, Jose R Azpiri-Lopez, Iris J Colunga-Pedraza, Jesus A Cárdenas-de la Garza, Raymundo Vera-Pineda, Martín Wah-Suárez, Rosa I Arvizu-Rivera, Adrian Martínez-Moreno, Ray E Ramos-Cázares, Francisco J Torres-Quintanilla and 3 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Rheumatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Global epidemiology of rheumatoid arthritis.Nature reviews. Rheumatology · 2022
    Review
  8. Article
  9. Article
  10. Mexican rheumatology: where do we stand?Rheumatology international · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dionicio A Galarza-DelgadoRheumatology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico. dgalarza@medicinauanl.mx.
Jose R Azpiri-LopezCardiology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Iris J Colunga-PedrazaRheumatology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Jesus A Cárdenas-de la GarzaInternal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Raymundo Vera-PinedaInternal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Martín Wah-SuárezInternal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Rosa I Arvizu-RiveraInternal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Adrian Martínez-MorenoInternal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Ray E Ramos-CázaresRheumatology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Francisco J Torres-QuintanillaCardiology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Aldo Valdovinos-BañuelosRheumatology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Jorge Antonio Esquivel-ValerioRheumatology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.
Mario A Garza-ElizondoRheumatology Division, Internal Medicine Department, "Dr. Jose Eleuterio Gonzalez" University Hospital, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with rheumatoid arthritis (RA) have a high risk for comorbid conditions which increase mortality, hospital admissions, costs of care and inability. To evaluate the prevalence of comorbidities in Mexican mestizo patients with RA and determine the associated risk factors. Cross-sectional study in which RA patients admitted to our outpatient clinic were consecutively enrolled. We collected data regarding demographics, disease characteristics and comorbidities at the time of the patient's visit to the clinic. We analyzed 225 patients. Their mean age was 55.7 ± 8.3 years; disease duration, 9.5 (3.8-15.5) years; female gender, 93.8%; Disease Activity Score using 28 joints-C-reactive protein, 3 (2-4); methotrexate use, 84.9%; use of any other conventional disease modifying anti-rheumatic drug, 65.7%; use of biological agents, 8%. The most frequently associated diseases were: hypertension, 29.8%; dyslipidemia, 27.1%; osteoporosis, 19.1%; diabetes, 12.4%; hypothyroidism, 6.2%; solid malignancies 4.4%. Risk factors were also evaluated, the most prevalent was overweight in 101 (44.9%) of our patients. A total of 71 (31.6%) had obesity. We also detected high blood pressure in 12.4%, hyperglycemia in 27.1% and hyperlipidemia in 49.8%. Due to the high frequency of comorbidities among RA patients, it is important to follow existing recommendations for their timely detection and management. Cardiovascular diseases must be evaluated with priority. The initial evaluation should include a thorough examination to prevent the deleterious effect of comorbidities in RA.

Indexed as

Indians, North AmericanAdultAgedAntirheumatic AgentsArthritis, RheumatoidComorbidityCross-Sectional StudiesFemaleHumansMaleMexicoMiddle AgedPrevalencePrognosisProspective StudiesRisk FactorsAntirheumatic AgentsComorbidityMexicoPrevalenceRheumatoid arthritis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.